Arca
Skip to content
Tools
Tools

GIPR: Gastric inhibitory polypeptide receptor

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

This is a receptor for GIP.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 1

Who Is On It, and How Far Along

Every drug ChEMBL records acting on GIPR, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide

Approved1

  • Tirzepatide

Phase 31

  • Retatrutide

Phase 20

    Phase 10

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      TirzepatideApprovedEli LillyProtein or peptideAgonistGastric inhibitory polypeptide receptor agonist213Boxed warning
      RetatrutidePhase 3Eli LillyProtein or peptideAgonistGastric inhibitory polypeptide receptor agonist11—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
      Fighting Osteoporosis With Risedronate Co-Therapy During IncretinTirzepatidePhase 3Not yet recruitingWake Forest University Health Sciences2026-11-17
      Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With ObesityTirzepatide—Not yet recruitingTechnical University of Munich2026-11-12
      Molecular and Microbiome Changes During Tirzepatide Treatment and Resistance Training in ObesityTirzepatide—Not yet recruitingTechnical University of Munich2026-11-12
      24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 ReceptorTirzepatideNot applicableNot yet recruitingPortuguese Oncology Institute, Coimbra2026-11-10
      Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight LossTirzepatide—Not yet recruitingTechnical University of Munich2026-11-10
      Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 DiabetesTirzepatideNot applicableNot yet recruitingGerman Diabetes Center2026-11-09
      Ocular Changes in Patients Using Tirzepatide or SemaglutideTirzepatide—RecruitingIstanbul University2026-11-09
      Changes in Body Composition Following Pharmacological Treatment for Obesity.Tirzepatide—Enrolling by invitationHospital San Carlos, Madrid2026-11-02
      Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are OverweightRetatrutidePhase 2RecruitingHudson Biotech2026-03-12
      A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightRetatrutidePhase 3Active, not recruitingEli Lilly and Company2026-01-22
      A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightRetatrutidePhase 3Active, not recruitingEli Lilly and Company2025-11-18
      A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)RetatrutidePhase 3RecruitingEli Lilly and Company2025-09-10
      A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainRetatrutidePhase 3Active, not recruitingEli Lilly and Company2025-06-24
      A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusRetatrutidePhase 1Active, not recruitingEli Lilly and Company2025-05-21
      A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityRetatrutidePhase 3Active, not recruitingEli Lilly and Company2025-03-05
      A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityRetatrutidePhase 3Active, not recruitingEli Lilly and Company2024-10-28

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Obesity disorder
      0.74
      Type 2 diabetes mellitus
      0.70
      Overweight
      0.52
      Abnormality of the skeletal system
      0.48
      Hypertensive disorder
      0.47
      Overnutrition
      0.47
      Obstructive sleep apnea syndrome
      0.47
      Nephrolithiasis
      0.44
      Abnormal urine sodium concentration
      0.41

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4383, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P48546, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.